Last updated: March 19, 2024
Sponsor: Indiana University
Overall Status: Terminated
Phase
3
Condition
Thoracotomy
Treatment
Gabapentin
Clinical Study ID
NCT05172570
10069
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion criteria:
- Pt undergoing open thoracotomy at Indiana University Hospital
- ASA 1,2,3 or 4
- Age 18 or older, male or female
Exclusion
Exclusion criteria:
- History of substance abuse in the past 6 months which would include heroin, marijuanaor any other illegal street drugs
- Patient on home dose of gabapentin or pregabalin
- Patient staying intubated after surgery
- Patient above 70yo
- Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day
- Known allergy or other contraindications to the study medications, which includegabapentin
- Patient unable to receive post-op epidural
- BMI above 40
- Creatinine clearance less than 30
Study Design
Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Gabapentin
Phase: 3
Study Start date:
April 06, 2021
Estimated Completion Date:
March 02, 2022
Study Description
Connect with a study center
indiana University
Indianapolis, Indiana 46202
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.